Pharm 101: Oxycodone

Class

Opioid analgesic


Pharmacodynamics
  • Moderate opioid agonist that acts mainly on mu receptors in brain and spinal cord, but also outside of CNS

Pharmacokinetics
  • PO administration, IR/SR formulations
  • Good oral absorption
  • High Vd
  • Low first pass metabolism (compared with morphine)
  • Duration of action 3-4 hours, longer if controlled released formulation
  • Hepatic metabolism by P450 to oxymorphone and noroxycodone
  • Renal excretion of metabolites

Clinical uses
  • Treatment of moderate to severe pain
  • 10 mg morphine = 4.5 mg oxycodone

Adverse effects with acute use of opioid analgesics
  • Respiratory depression
    • Due to inhibition of brainstem respiratory controls allowing less response to hypercapnea
  • CNS:
    • Nausea/vomiting
    • Sedation
    • Dysphoria
    • Delirium
    • Seizures
  • CVS:
    • Bradycardia
    • Hypotension
  • GIT:
    • Urinary retention
    • Constipation
    • Biliary colic
  • Skin:
    • Urticaria
    • Pruritus

Adverse effects with chronic use of opioid analgesics
  • Endocrine:
    • Hypogonadism
    • Immunosuppression
    • Increased feeding
    • Increased GH secretion
  • CNS:
    • Withdrawal effects
    • Dependence*, tolerance**, abuse, addiction
    • Hyperalgesia

Strategies to reduce development of dependence include:

  • Smaller doses at longer intervals
  • Multi-modal analgesia with non-opioid analgesics
  • Use of modified/SR formulations
  • Establish goals at start of treatment
  • Frequent evaluation of ongoing requirements

Tolerance:

  • Does not occur with miosis, constipation and seizures
  • There is a moderate degree of tolerance to bradycardia

Precautions/contraindications of opioid analgesics
  • Use of pure agonists with weak partial agonists:
    • e.g. buprenorphine with morphine
    • Can reduce analgesia, and induce withdrawal
  • Head injury:
    • CO2 retention secondary to respiratory depression causes cerebral vasodilation
  • Pregnancy:
    • Chronic use may precipitate dependence in fetus
  • Impaired pulmonary function:
    • Risk of acute respiratory failure
  • Impaired hepatic or renal function
  • Endocrine disease:
    • Patients with Addison’s disease and hypothyroidism (myxedema) may have prolonged and exaggerated responses to opioids
  • Drug interactions:
    • Other sedative-hypnotics
    • Antipsychotic agents: increased sedation and accentuation of cardiovascular effects (antimuscarinic and alpha blocking actions)
    • MAOIs: high incidence of hyperpyrexic coma, hypertension

Further reading

References

Pharm 101 700

Pharmacology 101

Top 200 drugs

MBBS (UWA) CCPU Emergency Medicine Trainee with interests in medical education, ECG interpretation, and the use of point-of-care ultrasound in the undifferentiated patient. Co-author of the LITFL ECG Library | Twitter

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.